West Pharmaceutical Services Dividends and Buybacks
Dividend criteria checks 0/6
West Pharmaceutical Services is a dividend paying company with a current yield of 0.24%.
Key information
0.2%
Dividend yield
2.7%
Buyback Yield
| Total Shareholder Yield | 2.9% |
| Future Dividend Yield | 0.6% |
| Dividend Growth | -15.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$0.840 |
| Payout ratio | 12% |
Recent dividend and buyback updates
Recent updates
West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 23% Below Its Share Price
Jan 10
West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)
Jan 08West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Not Quite Adding Up
Dec 23Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08West Pharmaceutical Services: The Run Might Be Over
Oct 18West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08West Pharmaceutical: Hard To Justify The Price
May 26West Pharmaceutical Q4 2022 Earnings Preview
Feb 15Stability and Growth of Payments
Fetching dividends data
Stable Dividend: WST is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: WST is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| West Pharmaceutical Services Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (WST) | 0.2% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Life Sciences) | 0.5% |
| Analyst forecast (WST) (up to 3 years) | 0.6% |
Notable Dividend: WST's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.42%).
High Dividend: WST's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (4.47%).
Earnings Payout to Shareholders
Earnings Coverage: WST is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: WST is not paying a notable dividend for the US market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 00:38 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Lawrence Marsh | Barclays |
| Derik de Bruin | BofA Global Research |